We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


John Lambert Appointed Chairman of Cambridge Biostability

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Cambridge Biostability Limited has announced that the Company has appointed John Lambert as Chairman of the Company with immediate effect.

John will take over the role from David Stone, who is currently Chairman and Chief Executive Officer.

John (aged 53) was President of Chiron Vaccines and Vice President to Chiron Corporation between 2001-2005. 

Between 1987 and 2000, he was at Aventis Pasteur where he rose to become the President of Aventis Pasteur MSD (the vaccines joint venture between Aventis Pasteur and Merck & Co) from 1998 to 2000. 

His working career began in the financial area in 1972, when he joined Servier Laboratories in the UK, which culminated with his appointment as Financial Director in 1981.

John has acted as the representative of the Vaccines Industry for the Developed World on the Board of the Global Alliance for Vaccines and Immunisation("GAVI") from 2004 to February 2005 , and was President of the European Vaccine Manufacturers Association ("EVM") from 2001 to 2003 (2 year tenure).

David Stone, Chief Executive of CBL, said, "John Lambert has had an internationally renowned & distinguished career in the field of vaccines and we are delighted that he has decided to become Chairman."

"He has a wealth of experience which will be invaluable to the business as it develops its role in the supply of stable vaccines to the developed and developing world."

John Lambert said, "CBL is undertaking crucial work in the stabilising of vaccines which is very exciting."

"I am committed to helping bring this innovative technology to a broad audience of people to help ease the cost and difficulties of immunisation, and believe that my prior experience in the vaccine world will help make this a reality."